Renova raising funds for pivotal gene therapy trials

Renova Therapeutics (San Diego, Calif.) plans to begin three pivotal studies by YE16 of gene therapy candidate RT-100 to treat congestive heart failure (CHF), CEO Jack Reich told BioCentury. He said the company also hopes to close a "substantial" series D round in May at a "very large increase in valuation" over its 2014 series C round.

JAMA Cardiology published results of a Phase II ADCY6; AC6) to heart muscle cells. ...